Literature DB >> 25205187

Translational hematology.

Klaus Geissler1.   

Abstract

Translational research is scientific research that helps to make findings from basic science useful for practical applications in the clinic. The successful use of a drug that interferes with the specific molecular pathophysiology of cancer remains the ultimate vision in cancer medicine. Translational research is a multistep process including the discovery of a cytogenetic/molecular aberration as well as the demonstration of its pathophysiological relevance and its druggability by in vitro experiments and in vivo animal models. Information obtained from preclinical research paves the way for clinical trials in which a drug of interest is developed until its clinical application. Modern pathophysiology-oriented anticancer drugs that have been developed by translational research are available for clinical applications since the beginning of this millennium. By using these drugs higher efficacy and lower toxicity could be achieved as compared with previous treatments. In this article, we will present some of the most prominent examples of this translational approach.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25205187     DOI: 10.1007/s10354-014-0306-9

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  109 in total

Review 1.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.

Authors:  Benjamin G Neel; Haihua Gu; Lily Pao
Journal:  Trends Biochem Sci       Date:  2003-06       Impact factor: 13.807

2.  A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations.

Authors:  W Matthews; C T Jordan; G W Wiegand; D Pardoll; I R Lemischka
Journal:  Cell       Date:  1991-06-28       Impact factor: 41.582

3.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

4.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

Review 5.  The anaplastic lymphoma kinase in the pathogenesis of cancer.

Authors:  Roberto Chiarle; Claudia Voena; Chiara Ambrogio; Roberto Piva; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

6.  Colony growth characteristics in chronic myelomonocytic leukemia.

Authors:  K Geissler; W Hinterberger; P Bettelheim; O Haas; K Lechner
Journal:  Leuk Res       Date:  1988       Impact factor: 3.156

7.  Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras.

Authors:  R Kalra; D C Paderanga; K Olson; K M Shannon
Journal:  Blood       Date:  1994-11-15       Impact factor: 22.113

8.  TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms.

Authors:  L W Ellisen; J Bird; D C West; A L Soreng; T C Reynolds; S D Smith; J Sklar
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

9.  Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.

Authors:  Doan T Le; Namie Kong; Yuan Zhu; Jennifer O Lauchle; Abigail Aiyigari; Benjamin S Braun; Endi Wang; Scott C Kogan; Michelle M Le Beau; Luis Parada; Kevin M Shannon
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

10.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.